Immunotherapy for Renal Cell Carcinoma
Author Information
Author(s): M. Itsumi, Katsunori Tatsugami
Primary Institution: Department of Urology, Graduate School of Medical Sciences, Kyushu University
Hypothesis
Immunotherapy can improve outcomes for patients with renal cell carcinoma (RCC) despite the disease's resistance to traditional treatments.
Conclusion
Immunotherapy shows promise in treating RCC, but the response rates remain low and long-term improvements are rare.
Supporting Evidence
- Immunotherapy has shown anti-tumor activity in RCC patients.
- Only 10%-20% of patients respond positively to cytokine treatments.
- Recent studies indicate the importance of immune regulation in RCC treatment.
Takeaway
Doctors are trying to use the body's immune system to fight kidney cancer, but it doesn't work for everyone.
Methodology
The review discusses various immunotherapy approaches and their effectiveness based on clinical trials.
Limitations
The review highlights the low response rates and challenges in evaluating the efficacy of immunotherapy compared to other treatments.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website